Remove Coronary Artery Disease Remove Plaque Remove Technology
article thumbnail

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

DAIC

a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. F.A.C.C.

article thumbnail

Photon-Counting CT Improves Coronary Artery Disease Assessment

DAIC

Coronary CT angiography for the suspected progression of known coronary artery disease in a 56-year-old female patient. mm (green outline) section thickness show the respective calcified plaque (arrowheads) and coronary stenosis (inset images). Curved multiplanar reconstructions with 0.6-mm

article thumbnail

Landmark Clinical Study in The Lancet Finds New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation at Least 10 Years in Advance

DAIC

Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. fold higher risk for cardiac mortality and 5.5-fold

article thumbnail

Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

DAIC

It further reported that these results underscore the strong and positive effect of the Cleerly products on clinical utility for patients with suspected coronary artery disease. “We He is the author of over 150 articles, book chapters, abstracts and other publications on advanced imaging technologies. Barcelona, Spain.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. After implantation, the locked phase establishes the maximum flow lumen and restores blood flow to treat symptoms of coronary artery disease (CAD).

article thumbnail

HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT

DAIC

a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024. milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. ,

article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue. vs. 28.7%; P=0.006). in the coming months.

Stents 105